# Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

> **NCT00293371** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 6 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** prednisone
- **DRUG:** vatalanib

## Key facts

- **NCT ID:** NCT00293371
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2012-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293371, "Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00293371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*